^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Biomarker Analysis of Zanubrutinib and Tislelizumab Combination Therapy in Patients with Relapsed/Refractory B-Cell Malignancies

Published date:
11/03/2022
Excerpt:
A higher ORR (1/2 [50%] vs 2/6 [33%]) and CR rate (1/2 [50%] vs 1/6 [16.7%]) was observed in patients with PD-L1+ tumor cells than in those without. High mRNA levels of CD3D (P < 0.05), HLA-DRA (P < 0.07), and LAG3 (P < 0.05) were enriched in responders...Patients with PD-L1 gene amplification, PD-L1+ tumor cells, and high mRNA levels of CD3D, HLA-DRA, and LAG3 in baseline tumor tissue may be more responsive to zanubrutinib and tislelizumab combination therapy.
DOI:
10.1182/blood-2022-168474